NasdaqGM - Delayed Quote • USD
Theravance Biopharma, Inc. (TBPH)
At close: May 17 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 3 | 3 |
| Avg. Estimate | -0.21 | -0.19 | -0.65 | 0.12 |
| Low Estimate | -0.24 | -0.25 | -0.79 | -0.61 |
| High Estimate | -0.19 | -0.14 | -0.43 | 0.98 |
| Year Ago EPS | -0.28 | -0.17 | -1 | -0.65 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 3 | 3 |
| Avg. Estimate | 15.45M | 16.59M | 72.48M | 81.26M |
| Low Estimate | 14.7M | 15.7M | 64.8M | 67.68M |
| High Estimate | 16.27M | 17.05M | 86.56M | 98.8M |
| Year Ago Sales | 13.75M | 15.69M | 57.42M | 72.48M |
| Sales Growth (year/est) | 12.40% | 5.70% | 26.20% | 12.10% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.21 | -0.21 | -0.15 | -0.25 |
| EPS Actual | -0.28 | -0.17 | -0.17 | -0.24 |
| Difference | -0.07 | 0.04 | -0.02 | 0.01 |
| Surprise % | -33.30% | 19.00% | -13.30% | 4.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.21 | -0.19 | -0.65 | 0.12 |
| 7 Days Ago | -0.21 | -0.17 | -0.68 | -0.4 |
| 30 Days Ago | -0.21 | -0.17 | -0.68 | -0.4 |
| 60 Days Ago | -0.22 | -0.17 | -0.64 | -0.32 |
| 90 Days Ago | -0.23 | -0.24 | -0.61 | -0.2 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 2 | 4 |
| Up Last 30 Days | 1 | -- | 2 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 3 | 2 | -- |
Growth Estimates
| CURRENCY IN USD | TBPH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 25.00% | -- | -- | 8.00% |
| Next Qtr. | -11.80% | -- | -- | 12.40% |
| Current Year | 35.00% | -- | -- | 5.60% |
| Next Year | 118.50% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 54.10% | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/14/2024 |
| Initiated | BTIG: Buy | 4/12/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/8/2023 |
| Maintains | HC Wainwright & Co.: Buy | 5/9/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 2/28/2023 |
| Maintains | SVB Leerink: Outperform | 11/17/2022 |
Related Tickers
TIL Instil Bio, Inc.
11.50
-2.54%
SYBX Synlogic, Inc.
1.6500
-1.79%
SPRO Spero Therapeutics, Inc.
1.5900
+1.27%
ASMB Assembly Biosciences, Inc.
14.53
-1.29%
AVIR Atea Pharmaceuticals, Inc.
3.6500
-1.35%
ALVR AlloVir, Inc.
0.7754
+3.19%
GLPG.AS Galapagos NV
27.14
-1.31%
GLPG Galapagos NV
29.63
+0.27%
RPHM Reneo Pharmaceuticals, Inc.
1.7500
+5.42%
NXTC NextCure, Inc.
1.6700
+1.21%